Gain Therapeutics, Inc. (NASDAQ:GANX - Get Free Report) has been given an average recommendation of "Moderate Buy" by the six ratings firms that are presently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating and five have issued a buy rating on the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $8.00.
A number of research analysts have commented on the stock. Roth Mkm reissued a "buy" rating and set a $10.00 target price on shares of Gain Therapeutics in a research report on Friday, December 19th. HC Wainwright reiterated a "buy" rating and set a $8.00 price objective on shares of Gain Therapeutics in a research note on Friday, December 19th. Finally, Weiss Ratings reissued a "sell (e+)" rating on shares of Gain Therapeutics in a research report on Monday, December 29th.
Check Out Our Latest Analysis on GANX
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Geode Capital Management LLC grew its stake in Gain Therapeutics by 2.9% during the 2nd quarter. Geode Capital Management LLC now owns 290,462 shares of the company's stock valued at $523,000 after purchasing an additional 8,251 shares during the last quarter. Sprott Inc. purchased a new position in shares of Gain Therapeutics in the fourth quarter worth about $39,000. Benedict Financial Advisors Inc. lifted its holdings in shares of Gain Therapeutics by 55.6% during the third quarter. Benedict Financial Advisors Inc. now owns 35,000 shares of the company's stock worth $62,000 after purchasing an additional 12,500 shares during the period. Commonwealth Equity Services LLC purchased a new stake in Gain Therapeutics in the fourth quarter valued at approximately $41,000. Finally, Millennium Management LLC purchased a new stake in shares of Gain Therapeutics in the 4th quarter valued at $45,000. 11.97% of the stock is currently owned by hedge funds and other institutional investors.
Gain Therapeutics Stock Performance
Shares of Gain Therapeutics stock opened at $2.62 on Wednesday. The company has a current ratio of 2.52, a quick ratio of 2.52 and a debt-to-equity ratio of 0.05. The stock's fifty day moving average price is $2.17 and its 200-day moving average price is $2.37. The firm has a market cap of $100.77 million, a P/E ratio of -4.30 and a beta of -0.03. Gain Therapeutics has a 12 month low of $1.41 and a 12 month high of $4.34.
Gain Therapeutics Company Profile
(
Get Free Report)
Gain Therapeutics, Inc NASDAQ: GANX is a clinical-stage biopharmaceutical company focused on precision therapeutics for neurodegenerative and rare diseases. The company leverages its proprietary allosteric modulation platform, AlphaTarget, to discover and optimize small molecule modulators that bind to non-active sites on target proteins. By correcting protein folding and function, Gain aims to provide disease-modifying treatments with improved selectivity and reduced off-target effects.
Gain's lead clinical candidate, GT-022, is being developed for Gaucher disease, a rare lysosomal storage disorder characterized by deficient enzyme activity.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Gain Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gain Therapeutics wasn't on the list.
While Gain Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
We are about to experience the greatest A.I. boom in stock market history...
Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.
That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.
- The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
- The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
- Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.
Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.
And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...
Simply click the link below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
